» Articles » PMID: 6702493

Treatment of Digital Vasospastic Disease with the Calcium-entry Blocker Nifedipine

Overview
Journal Acta Med Scand
Specialty General Medicine
Date 1984 Jan 1
PMID 6702493
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Eight patients with vasospastic disease of the digital arteries were treated with the calcium-entry blocker nifedipine (capsules), 10 mg t.i.d. and 20 mg t.i.d. The degree of cold-induced digital vasospasm after local cooling of the finger to 15 and 10 degrees C, measured by strain-gauge technique, was significantly decreased by nifedipine. The degree of reduction was dose-dependent. All patients improved symptomatically. The side-effects of the drug were minor but became more prominent when the dose was increased. We conclude that nifedipine is a useful agent in the treatment of digital vasospastic disease.

Citing Articles

Controlled double blind trial of nisoldipine in the treatment of idiopathic Raynaud's phenomenon.

Gjorup T, Hartling O, Kelbaek H, Nielsen S Eur J Clin Pharmacol. 1986; 31(4):387-9.

PMID: 3816916 DOI: 10.1007/BF00613511.


Clinical and rheological effects of nifedipine in Raynaud's phenomenon.

Waller D, Challenor V, Francis D, Roath O Br J Clin Pharmacol. 1986; 22(4):449-54.

PMID: 3533127 PMC: 1401145. DOI: 10.1111/j.1365-2125.1986.tb02916.x.


The effect of isradipine, a new calcium-channel antagonist, in patients with primary Raynaud's phenomenon: a single-blind dose-response study.

Leppert J, Jonasson T, Nilsson H, Ringqvist I Cardiovasc Drugs Ther. 1989; 3(3):397-401.

PMID: 2535054 DOI: 10.1007/BF01858110.


Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Sorkin E, Clissold S, Brogden R Drugs. 1985; 30(3):182-274.

PMID: 2412780 DOI: 10.2165/00003495-198530030-00002.


Use of nifedipine in hypertension and Raynaud's phenomenon.

Kiowski W, Erne P, Buhler F Cardiovasc Drugs Ther. 1990; 4 Suppl 5:935-40.

PMID: 2076403 DOI: 10.1007/BF02018296.